Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

P351

Faecal calprotectin correlates well with extent of active endoscopic inflammation in patients with ulcerative colitis

Authors:

D. Chayut1, M. Kaplan2, Y. Chowers3, M. Waterman*3

1The Technion - Israel Institute of Technology, B. Rappaport Faculty of Medicine, Haifa, Israel, 2Rambam Health Care Campus, Department of Laboratory Medicine, Haifa, Israel, 3Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel

P352

Melanoma in a population-based Australian inflammatory bowel disease cohort

Authors:

G. Hume*

University of Queensland, School of Medicine, Brisbane, Australia

P353

Endoscopy-based management within the first year after surgery decreases the risk of clinical and surgical postoperative recurrences in Crohn’s disease

Authors:

A.-L. Boucher1, B. Pereira2, S. Decousus3, M. Goutte1, 4, F. Goutorbe1, A. Dubois5, J. Gagnière5, C. Borderon6, J. Joubert3, D. Pezet5, M. Dapoigny1, P. Dechelotte3, G. Bommelaer1, 4, A. Buisson*1, 4

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, 2DRCI, Biostatistics Unit, Clermont-Ferrand, France, 3University Hospital Estaing, Pathology Department, Clermont-Ferrand, France, 4UMR 1071 Inserm/Université d’Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, 5CHU Estaing, Department of Digestive surgery, Clermont-Ferrand, France, 6University Hospital Estaing, Paediatrics Department, Clermont-Ferrand, France

P354

A prospective randomised study: 2 mg/kg/d of azathioprine is an appropriate dosage for Chinese patients with Crohn’s disease

Authors:

Y. Zhang*, J. Xia, Q. Cao

Sir Runrun Shaw Hospital, Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China

P355

Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis

Authors:

D. Seah*1, 2, M. Choy1, 2, 3, A. Gorelik4, F. Macrae5, M. Sparrow6, W.R. Connell3, G. Moore7, D. Van Langenberg8, P. De Cruz1, 2

1Austin Health, Department of Gastroenterology, Melbourne, Australia, 2University of Melbourne, Department of Medicine, Melbourne, Australia, 3St Vincent’s Hospital, Department of Gastroenterology, Melbourne, Australia, 4Royal Melbourne Hospital, Melbourne EpiCentre, Melbourne, Australia, 5Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia, 6The Alfred Hospital, Department of Gastroenterology, Melbourne, Australia, 7Monash Health, Department of Gastroenterology, Melbourne, Australia, 8Eastern Health, Department of Gastroenterology, Melbourne, Australia

P356

Efficacy and safety of certolizumab pegol in Crohn’s disease patients with loss of response or intolerance to previous anti-TNF

Authors:

I. Ferrer Bradley*1, I. Marín2, N. Maroto1, M. Mora1, E. Hinojosa1, B. López2, L. Menchén2, J. Hinojosa1

1Hospital de Manises, Gastroenterology, Valencia, Spain, 2Hospital Gregorio Marañón, Gastroenterology, Madrid, Spain

P357

Do you think that complementary and alternative medicine use is frequent amongst inflammatory bowel disease patients: Forget it!—results from a comparative study

Authors:

M. Rutka*1, T. Ferenci2, F. Nagy1, Z. Szepes1, K. Farkas1, A. Bálint1, R. Bor1, A. Milassin1, Z. Lénárt1, T. Molnar1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2John von Neumann Faculty of Informatics of Óbuda University, Budapest, Hungary

P358

Six-year adalimumab efficacy in steroid-dependent Crohn’s disease patients: a prospective ‘real-life’ study

Authors:

S. Renna*1, M. Cappello2, R. Dimitri3, F. Mocciaro3, M. Mazza2, M. Giunta4, M. Mendolaro2, E. Orlando1, M. Affronti1, A. Craxì2, M. Cottone1, A. Orlando1

1”Villa Sofia-Cervello” Hospital, Division of Internal Medicine, Palermo, Italy, 2Palermo University, Department of Gastroenterology and Hepatology, Palermo, Italy, 3Arnas Civico Di Cristina Benfratelli Hospital, Gastroenterology and Endoscopy Unit, Palermo, Italy, 4”Villa Sofia-Cervello” Hospital, Division of Internal Medicine,, Palermo, Italy

P359

Correlation of simple laboratory tests with clinical disease activity scores in inflammatory bowel disease

Authors:

O. Tayfur Yurekli, H. Koseoglu, M. Basaran, N.S. Buyukasik, a. Demirezer Bolat, F.E. Akin*, m. Tahtaci, e. Selvi, O. Ersoy

Ankara Ataturk Research and Education Hospital, Gastroenterology, Ankara, Turkey

P360

A randomised, assessor-blinded, multicentre trial comparing the efficacy, safety, and tolerability of a new tailored dosing regimen to day-before dosing regimen of colon cleansing agent used before colonoscopy

Authors:

R. Kiesslich*1, C. Angelin2, K. Raymond2, W. Man A Hing3, J. Masure3, M. Stoltenberg2

1Helios Dr. Horst Schmidt Kliniken, Department of Internal Medicine II, Wiesbaden, Germany, 2Ferring Pharmaceuticals Kay Fiskers Plads 11, Copenhagen, Denmark, 3Ferring International Centre S.A, St Prex, Switzerland

P361

Adherence to faecal calprotectin test in patients with inflammatory bowel disease

Authors:

C. Maréchal*1, I. Gastin2, C. Baumann2, B. Dirrenberger1, J.-L. Gueant2, L. Peyrin-Biroulet1

1University hospital, Gastro-enterology, Vandoeuvre-les-Nancy, France, 2Inserm U954, Vandoeuvre-les-Nancy, France

P362

Anti-virus treatment against CMV in patients with ulcerative colitis by the PCR monitoring for mucosal CMV-DNA

Authors:

M. Tanaka*, T. Takagi, Y. Toyokawa, Y. Hotta, K. Uchiyama, Y. Naito, Y. Itoh

Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 6028–566, Japan

P363

Efficacy and safety of golimumab in patients with ulcerative colitis: a prospective multicentre study

Authors:

D. Varvara1, G. Costantino2, A.C. Privitera3, B. Principi4, M. Cappello5, S. Mazzuoli6, P. Paiano7, A. Tursi8, P. Paese9, W. Fries10, A. Andriulli1, F. Bossa*1

1IRCCS Casa Sollievo della Sofferenza, Gastroenterology, San Giovanni Rotondo, Italy, 2University of Messina, Clinical and experimental Medicine, Messina, Italy, 3Ospedale Cannizzaro, Chirurgia, Catania, Italy, 4University of Bari, Gastroenterology, Bari, Italy, 5University of Palermo, Gastroenterology, Palermo, Italy, 6Ospedale San Nicola Pellegrino, Gastroenterology, Trani, Italy, 7Ospedale di poggiardo, Gastroenterology, Poggiardo, Italy, 8ASL BAT, Gastroenterology, Andria, Italy, 9Ospedale Annunziata, Gastroenterology, Cosenza, Italy, 10University of Messina, Clinical and Experimental Medicine, Messina, Italy

P364

The efficacy of initial treatment with infliximab without previous conventional therapy in patients with moderate-to-severe ulcerative colitis

Authors:

O. Prymak*

Medical Clinical Investigational Centre of the Medical Centre LLC Health Clinic, Vinnytsia, Ukraine

P365

Real-world effectiveness of adalimumab in patients with ulcerative colitis

Authors:

A. Armuzzi*1, C. Taxonera2, J. Panes3, P. Lakatos4, N. Fisseha5, B. Pappalardo5

1Complesso Integrato Columbus-Gemelli University Hospital Foundation, IBD Unit, Rome, Italy, 2Hospital Clínico San Carlos, IdiSSC, Madrid, Spain, 3Hospital Clínic Barcelona, Gastroenterology, Barcelona, Spain, 4Semmelweis University, First Department of Medicine, Budapest, Hungary, 5AbbVie Inc, North Chicago, Illinois, United States

P366

Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis

Authors:

G. Losurdo*, A. Iannone, A. Contaldo, E. Ierardi, A. Di Leo, M. Principi

University of Bari, DETO, Bari, Italy

P367

Lower quality of life, more active disease and increased healthcare costs due to non-adherence in inflammatory bowel disease

Authors:

M. Severs*1, M.-J. Mangen2, H. H. Fidder1, M. E. van der Valk1, M. van der Have1, A. A. van Bodegraven3, 4, C. H. M. Clemens5, G. Dijkstra6, J. M. Jansen7, D. J. de Jong8, N. Mahmmod9, P. C. van de Meeberg10, A. E. van der Meulen- de Jong11, M. Pierik12, C. Y. Ponsioen13, M. J. L. Romberg- Camps3, P. D. Siersema1, J. R. Vermeijden14, J. van der Woude15, P. N. Zuithoff16, B. Oldenburg1

1University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands, 2University Medical Centre Utrecht, Julius Centre for health sciences and primary care, Utrecht, Netherlands, 3ORBIS medical Centre, Gastroenterology and Hepatology, Sittard, Netherlands, 4VU medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 5Diaconessenhuis, Gastroenterology and Hepatology, Leiden, Netherlands, 6University Medical Centre Groningen, Gastroenterology and Hepatology, Groningen, Netherlands, 7Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, 8University Medical Centre St Radboud, Gastroenterology and Hepatology, Nijmegen, Netherlands, 9Antonius Hospital, Gastroenterology and Hepatology, Nieuwegein, Netherlands, 10Slingeland Hospital, Gastroenterology and Hepatology, Doetinchem, Netherlands, 11Leiden University Medical Centre, Gastroenterology and Hepatology, Leiden, Netherlands, 12University Medical Centre Maastricht, Gastroenterology and Hepatology, Maastricht, Netherlands, 13Academic Medical Centre Amsterdam, Gastroenterology and Hepatology, Amsterdam, Netherlands, 14Meander Medical Centre, Gastroenterology and Hepatology, Amersfoort, Netherlands, 15Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, Netherlands, 16University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, Netherlands

P368

Risk factors for serious infections in elderly patients receiving infliximab and other Crohn’s disease therapies: TREAT™ registry data

Authors:

G. Lichtenstein1, W. Langholff2, B. Feagan*3, R. Cohen4, B. Salzberg5, J. Popp6, R. Nissinen7, W. J. Sandborn8

1University of Pennsylvania Perelman School of Medicine, Division of Gastroenterology, Philadelphia, Pennsylvania, United States, 2Janssen R & D, LLC, Spring House, Pennsylvania, United States, 3Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, 4University of Chicago Medical Centre, Department of Gastroenterology, Chicago, Illinois, United States, 5Atlanta Gastroenterology Specialists PC, Atlanta, Georgia, United States, 6Janssen Pharmaceuticals, Horsham, Pennsylvania, United States, 7Janssen Biologics BV, Leiden, Netherlands, 8University of California San Diego, Division of Gastroenterology, La Jolla, California, United States

P369

Improvement in patient-reported outcomes in 2 Phase 3 studies of tofacitinib in patients with moderately to severely active ulcerative colitis

Authors:

J. Panés*1, C. Su2, A. Marren2, D. Yu2, D. Woodworth2, H. Zhang2, P. Healey3

1Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2Pfizer Inc, Collegeville, United States, 3Pfizer Inc, Groton, United States

P370

Treatment patterns in a managed care project with inflammatory bowel disease patients in Germany: CEDnetz study

Authors:

B. Bokemeyer*1, J. Langbrandtner2, P. Jessen3, J. Büning4, S. Schreiber5, H. Raspe2, A. Hüppe2

1Gastroenterology Practice Minden, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany, Minden, Germany, 2Universität zu Lübeck, Institut für Sozialmedizin und Epidemiologie, Lübeck, Germany, 3Gastroenterology Practice, Gastroenterology, Altenholz, Germany, 4University Hospital Schleswig-Holstein, Campus Lübeck, Medical Department I, Gastroenterology, Lübeck, Germany, 5Christian-Albrechts-Universität, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany